3 news items
GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink
GLYC
6 May 24
and regulatory experts and are committed to submitting a comprehensive data analysis for presentation at an upcoming medical meeting
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GLYC
6 May 24
data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GLYC
27 Mar 24
and therapeutic area experts. ASH RC fosters partnerships to accelerate progress and improve outcomes for people living with SCD by expediting
- Prev
- 1
- Next